review Open AccessTop 1% cited
Top 10 Challenges in Cancer Immunotherapy
Immunity · 2020 · Vol. 52(1) · pp. 17–35
Priti S. HegdeDaniel S. Chen✉(IGM Biosciences (United States))
Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCAR-T cell therapy researchImmunotherapyCancer immunotherapyCancerCancer treatmentClinical trialIntensive care medicineBiologyMedicineBioinformaticsInternal medicine
MeSH terms
HumansImmunotherapyModels, BiologicalNeoplasmsTumor Microenvironment
Funding
- F. Hoffmann-La Roche
Citations
2,223
FWCI
114.06
field-weighted impact
References
201
Percentile
100%
vs. same field & year
Citations per year
Cited by
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
Cancer Cell · 2023 · 3,276 citations
References
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
New England Journal of Medicine · 2015 · 9,308 citations
Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma
BMC Genomics · 2014 · 381 citations
Oncology Meets Immunology: The Cancer-Immunity Cycle
Immunity · 2013 · 6,760 citations
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
Clinical Pharmacology & Therapeutics · 2009 · 756 citations
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy
AIDS · 2014 · 589 citations
The immune contexture in human tumours: impact on clinical outcome
Nature reviews. Cancer · 2012 · 4,857 citations
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Science · 2015 · 7,864 citations
The Transcription Factor Myc Controls Metabolic Reprogramming upon T Lymphocyte Activation
Immunity · 2011 · 2,061 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.